• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New $1b NIH center will tackle early-stage drug development to ease industry risk of failure

New $1b NIH center will tackle early-stage drug development to ease industry risk of failure

February 7, 2011
CenterWatch Staff

A billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research.

According to the Pharmaceutical Research Manufacturers of America (PhRMA), the biopharmaceutical research sector invested an estimated $65.3 billion to discover and develop new medicines in 2009. Yet, on average, one medicine was approved for every 10,000 molecules studied. As a result, it has become increasingly difficult for the pharmaceutical industry to continue supporting the cost and time required for new drug discovery.

The center, to be called the National Center for Advancing Translational Sciences, was proposed to address widespread concerns about the slowing pace of new drugs coming out of the pharmaceutical industry. Health and Human Services Secretary Kathleen Sebelius told Congress the center, which will be set up within the National Institutes of Health (NIH), will be up and running by October.

The federal research center could have a significant impact, in particular, on the development of new treatments for rare and orphan diseases. Many discoveries have been made recently in this area, but drug sponsors haven’t shown interest in spending the time and money necessary to pursue these treatments since the diseases affect a limited number of patients. To support development in these areas, NIH Director Francis Collins said NIH-funded researchers could explore compounds through early stages in the drug-development pipeline to “de-risk” projects that would otherwise be disregarded.

The idea behind the center, which Collins endorsed, will be for NIH investigators to evaluate novel potential drug targets and develop promising compound leads, doing some work that has traditionally been done by drug companies, in order to provide enough information for pharmaceutical companies to invest in further drug development. According to Collins, the goal is to develop each project far enough to interest industry in finishing the job. For a new molecular entity to treat a common disease, drug-sponsor interest would be high early in the project. But a treatment for a rare disease, on the other hand, might not interest a drug sponsor until later in development.

David Wheadon, senior vice president of PhRMA, said the biopharmaceutical industry is “encouraged” by Collin’s goal to focus on early-stage research in the hope of improving ultimate success rates in drug development.

In addition, the new center won’t try to compete with drug companies in developing medications for common diseases. Instead, the NIH website said it will focus on neglected diseases and on drugs for diseases that “attract little commercial” attention. Companies including Pfizer, Novartis and Sanofi-aventis recently have shown interest in developing drugs for rare diseases.

Wheadon said the collaboration between industry, NIH and academia can help drive innovation in drug development, particularly in early-stage research. “Bold and ambitious proposals, such as Dr. Collins’, will be key to how we collectively progress in discovering novel compounds for addressing patients’ unmet medical needs,” he said.

While Wheadon called the new center worthwhile, he also noted that biopharmaceutical companies create the “vast majority” of new medicines from start to finish, saying, “The fact remains that biopharmaceutical companies today and in the future will play a pivotal role.”

 —Karyn Korieth

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing